TCF7L2 and diabetes mellitus: As a study case, TCF7L2 is chosen in that it is a key WNT downstream regulator which is implicated in cancers and diabetes, as well as its alternative splicing generates protein variants with differential promoter-binding and transcriptional activation [31, 32, 46].